ClinicalTrials.gg
CompletedNCT01421134RESOLVE 1Updated Jul 15, 2016Results posted

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose

A Phase 3 interventional study of Lurasidone and Placebo in Major Depressive Disorder With Mixed Features, sponsored by Sumitomo Pharma America, Inc.. Completed at 43 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-07-15.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
211
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Depression by Sumitomo Pharma Co., Ltd. — none open to participants now, none under way, none of them phase 3. Depression · Sumitomo Pharma Co., Ltd..

Enrollment
6th of 11
211 · median 211
Started
2011
with 1 other
Phase 3
9 of 11
none open now
Registered
5th of 11
by date

Among the 11 studies in Depression by Sumitomo Pharma Co., Ltd., this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 5th registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

None of the 11 studies in Depression by Sumitomo Pharma Co., Ltd. is open now. The open studies under Depression, anywhere →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Depression by Sumitomo Pharma Co., Ltd. as a file.
02

Study summary

Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.

03

Conditions studied

  • Major Depressive Disorder With Mixed Features

Browse trials for

Keywords

  • depression
  • Lurasidone
  • Latuda
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject provides written and is willing and able to comply with the protocol in the opinion of the Investigator.
  • Subject is 18 to 75 years of age, inclusive.
  • Subject has MDD (diagnosed by , and confirmed by the Structured - Clinical Interview for DSM-IV Disorders - Clinical Trial version [SCID-CT]).
  • Subject is currently experiencing a major depressive episode (diagnosed by DSM IV TR; at least 2 weeks in duration) AND two or three of the following manic symptoms occurring on most days over at least the last 2 weeks (confirmed by the SCID-CT modified for Study D1050304):

    • Elevated, expansive mood
    • Inflated self-esteem or grandiosity
    • More talkative than usual or pressure to keep talking
    • Flight of ideas or subjective experience that thoughts are racing
    • Increase in energy or goal-directed activity (either socially, at work or school, or sexually)
    • Increased or excessive involvement in activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)
    • Decreased need for sleep (feeling rested despite sleeping less than usual; to be contrasted from insomnia)

Exclusion criteria

Exclusion Criteria:

  • Subject has Axis I or Axis II diagnosis other than MDD that has been the primary focus of treatment within the 3 months prior to screening.
  • Subject answers "yes" to "Suicidal Ideation" Item 4 or 5 on the C-SSRS (at time of evaluation) at screening or baseline visit.
  • Subject has attempted suicide within the past 3 months.
  • Subject has a lifetime history of any bipolar I manic or mixed manic episode.
  • Subject has any abnormal laboratory parameter at screening that indicates a medical condition as determined by the Investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
211 participants (actual)

Study arms

  • Experimental
    Lurasidone

    Lurasidone 20, 40 or 60 mg

    Drug: Lurasidone

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

  • 20, 40, 60 mg, flexible dose, once daily PM 6 weeks

    Also known as: Latuda

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores

    The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

    Time frame: Baseline to Week 6

Secondary outcomes

  1. Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score

    The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

    Time frame: Baseline to Week 6

  2. Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score

    The YMRS is an 11-item clinician-rated instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 individual items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.

    Time frame: Baseline to Week 6

  3. Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score

    The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).

    Time frame: Baseline to Week 6

  4. Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score

    The HAM-A is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.

    Time frame: Baseline to Week 6

  5. Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).

    Time frame: Baseline to Week 6

  6. Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)

    Time frame: Baseline to Week 6

07

Results

Posted Oct 9, 2015

Participant flow

Participant flow — Overall Study
MilestoneLurasidonePlacebo
Started109102
Completed10287
Not completed715
Withdrew: Adverse event35
Withdrew: Lack of efficacy24
Withdrew: Protocol violation03
Withdrew: Withdrawal by subject11
Withdrew: Administrative01
Withdrew: Lost to follow-up11

Outcome measures

PrimaryMean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores

The MADRS consists of 10 items, each rated on a Likert scale, from 0="Normal" to 6="Most Severe". The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores
units on a scaleLurasidonePlacebo
Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores-20.5 ± 0.95-13.0 ± 1.00
Statistical analysis
  • Lurasidone vs Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -7.5 · 95% CI -10.2 to -4.8
SecondaryMean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score

The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= 'Normal, not at all ill' to 7= 'Among the most extremely ill patients'. A higher score is associated with greater illness severity.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score
units on a scaleLurasidonePlacebo
Mean Change From Baseline to the 6-week Study Endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) Score-1.83 ± 0.109-1.18 ± 0.115
Statistical analysis
  • Lurasidone vs Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -0.65 · 95% CI -0.96 to -0.34
SecondaryMean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score

The YMRS is an 11-item clinician-rated instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 individual items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score
units on a scaleLurasidonePlacebo
Mean Change From Baseline to Week 6 in the Young Mania Rating Scale (YMRS) Total Score-7.0 ± 0.35-4.9 ± 0.37
Statistical analysis
  • Lurasidone vs Placebo · Mixed Models Analysis · p = <0.0001 · Least square mean difference: -2.1 · 95% CI -3.1 to -1.1
SecondaryMean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score

The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient's life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1-3 (mild), 4-6 (moderate), 7-9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score
units on a scaleLurasidonePlacebo
Mean Change From Baseline to Week 6 in the Sheehan Disability Scale (SDS) Total Score-11.2 ± 0.88-6.4 ± 0.88
Statistical analysis
  • Lurasidone vs Placebo · ANCOVA · p = 0.0001 · Least square mean difference: -4.8 · 95% CI -7.2 to -2.4
SecondaryMean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score

The HAM-A is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.

Time frame:
Baseline to Week 6
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score
units on a scaleLurasidonePlacebo
Mean Change From Baseline to Week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) Total Score-9.9 ± 0.58-5.4 ± 0.59
Statistical analysis
  • Lurasidone vs Placebo · ANCOVA · p = <0.0001 · Least square mean difference: -4.5 · 95% CI -6.1 to -2.9
SecondaryPercentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).
Time frame:
Baseline to Week 6
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).
percentage of subjectsLurasidonePlacebo
Percentage of Subjects Who Achieve a Response, Defined as ≥ 50% Reduction From Baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 (LOCF).64.830.0
Statistical analysis
  • Lurasidone vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 6.615 · 95% CI 3.251 to 13.459Odds Ratio was based on a logistic regression of response, with treatment group, baseline MADRS total score, and pooled center as fixed effects.
SecondaryPercentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)
Time frame:
Baseline to Week 6
Reported as:
Number · percentage of subjects
Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)
percentage of subjectsLurasidonePlacebo
Percentage of Subjects Who Achieve a Remission, Defined as a Montgomery-Asberg Depression Rating Scale (MADRS) Total Score of ≤ 12 at Week 6 (LOCF)49.123.0
Statistical analysis
  • Lurasidone vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.270 · 95% CI 2.105 to 8.663

Adverse events

Collected over 6 Weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurasidone—1/109 (0.9%)31/109 (28.4%)
Placebo—0/100 (0%)29/100 (29%)
Most frequent serious events
Most frequent serious events
EventLurasidonePlacebo
Depression SuicidalPsychiatric disorders1/1090/100
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLurasidonePlacebo
InsomniaPsychiatric disorders6/10911/100
AnxietyPsychiatric disorders4/1099/100
NauseaGastrointestinal disorders7/1092/100
HeadacheNervous system disorders6/1096/100
SomnoelenceNervous system disorders5/1091/100
Abdominal discomfortGastrointestinal disorders4/1091/100
AkathisiaNervous system disorders4/1092/100
DizzinessNervous system disorders4/1093/100
Dry mouthGastrointestinal disorders3/1091/100
Urinary Tract InfectionInfections and infestations1/1092/100

Baseline characteristics

Two subjects were randomized in error and were not treated.

Age, Categorical
Age, Categorical(Participants)LurasidonePlaceboTotal
<=18 years101
Between 18 and 65 years10696202
>=65 years246
Age, Continuous
Age, Continuous(years)LurasidonePlaceboTotal
Mean43.6 ± 12.0846.4 ± 12.0144.9 ± 12.10
Sex: Female, Male
Sex: Female, Male(Participants)LurasidonePlaceboTotal
Female7372145
Male362864
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LurasidonePlaceboTotal
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American141226
White9486180
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)LurasidonePlaceboTotal
Russian Federation181331
United States342660
Ukraine303262
United Kingdom134
Serbia262652
08

Study locations

43 sites
  • Birmingham Psychiatry Pharmaceutical Studies, Inc.
    Birmingham, Alabama 35226, United States
  • Synergy Clinical Research Center
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network Inc.
    Garden Grove, California 92845, United States
  • Stanford -VA Palo Alto Health Care System
    Palo Alto, California 94304, United States
  • Clinical Innovations Inc.
    Riverside, California 92506, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Florida Clinical Research Center, LLC
    Sarasota, Florida 34201, United States
  • Massachusetts General Hospital - Center for Anxiety and Traumatic Stress Disorders
    Boston, Massachusetts 02114, United States
  • St. Charles Psychiatric Associates/Midwest Research Group
    St. Charles, Missouri 63301, United States
  • Social Psychiatric Research Inst. (SPRI) Clinical Trials
    Brooklyn, New York 11235, United States
  • Village Clinical Research Inc.
    New York, New York 10003, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Behavioral Medical Research of Staten Island
    Staten Island, New York 10305, United States
  • Psychiatry and Behavioral Sciences, Duke
    Durham, North Carolina 27705, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • CRI Worldwide - Kirkbride
    Philadelphia, Pennsylvania 19139, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Dept. of Psychiatry, UT Southwestern Medical Center
    Dallas, Texas 75390-8849, United States
  • Grayline Clinical Drug Trials
    Wichita Falls, Texas 76309, United States
  • Municipal Healthcare Institution"City Clinical Hospital #2, n.a. V.I. Razumovsky" of Healthcare Committee of Administration of Municipal Entity "City of Saratov"
    Saratov, 410028, Russian Federation
  • State Healthcare Institution, Saratov Regional Psychiatric Hospital of St.Sophia,
    Saratov, 410060, Russian Federation
  • Saint Nicholas Psychiatric Hospital.
    St. Petersburg, 190121, Russian Federation
  • City Psychiatry Hospital 4 (Saint Petersburg Psychiatric Admitting Unit)
    St. Petersburg, 191119, Russian Federation
  • Federal State Institution "Saint-Petersburg Research psychoneurogical Institute named after V.M. Bekhtereva"
    St. Petersburg, 193167, Russian Federation
  • Limited Liability Company "Research-And-Educational Centre of Psychotherapy "Podderzhka"
    Stavropol, 355000, Russian Federation
  • Institute of Mental Health
    Belgrade, 11000, Serbia
  • Psychiatric Clinic, Clinical Hospital Center"Dr. Dragisa Misovic-Dedinje"
    Belgrade, 11000, Serbia
  • Health Centre Cacak Department of Psychiatry
    Cacak, 32000, Serbia
  • Clinical Center Nis, Psychiatric Clinic
    Gornja Toponica, 18201, Serbia
  • Clinical Center Kragujevac, Psychiatric Clinic
    Kragujevac, 34000, Serbia
  • Clinic for Mental Health, Clinical Center Nis
    Nis, 18000, Serbia
  • Special Hospital for Psychiatric Diseases "Sveti Vracevi"
    Vojvodina, 23330, Serbia
  • Special Hospital for Psychiatric Diseases "Dr Slavoljub Bakalovic"
    Vrsac, 26300, Serbia
  • General Hospital "Djordje Joanovic" Psychiatric Dept.
    Zrenjanin, 23000, Serbia
  • Dnipropetrovsk Regional Clinical Hospital named Mechnikov
    Dnipropetrovsk, 49005, Ukraine
  • State Institution "Institute of Neurology, Psychiatry and Narcology NAMS of Ukraine", Dep. of Clinical, Social and Child Psychiatry
    Kharkiv, 61068, Ukraine
  • Communal Institution of Kyiv Regional Council "Regional Psychiatric and Narcological Medical Association "Psychiatric Dept. #10 and Psychiatric Dept. #2
    Kyiv, 08631, Ukraine
  • "Lugansk State Medical University"Chair of Psychiatry, Narcology and Medical Psychology; Lugansk Regional Clinical Psychoneurological Hospital, Dispensary Dept. for adults
    Lugansk, 91045, Ukraine
  • Municipal Institution "Lviv Regional State Clinical Psychiatric Hospital, Department #20
    Lviv, 79021, Ukraine
  • Odesa Regional Psychoneurological Dispensary, Outpatient Dept.
    Odesa, 65014, Ukraine
  • Vinnytsya National Medical University n.a. M.I. Pyrogov, Dept. of Psychiatry and Narcology, Vinnytsya Regional Psychoneurological Hospital n.a. O.I. Yushchenko, Dept. no. 14, Dept. no 15
    Vinnytsya, 21018, Ukraine
  • MAC Clinical Research Limited
    Cannock, WS11 0BN, United Kingdom
  • MAC Clinical Research Limited
    Manchester, M32 0UT, United Kingdom
09

References and documents

Publications

  • Clayton AH, Tsai J, Mao Y, Pikalov A, Loebel A. Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial. J Clin Psychiatry. 2018 Aug 7;79(5):18m12132. doi: 10.4088/JCP.18m12132. PubMed 30086213 ↗
  • Targum SD, Pendergrass JC, Lee S, Loebel A. Ratings surveillance and reliability in a study of major depressive disorder with subthreshold hypomania (mixed features). Int J Methods Psychiatr Res. 2018 Dec;27(4):e1729. doi: 10.1002/mpr.1729. Epub 2018 Jun 26. PubMed 29943445 ↗
  • Targum SD, Suppes T, Pendergrass JC, Lee S, Silva R, Cucchiaro J, Loebel A. Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jul 4;68:9-14. doi: 10.1016/j.pnpbp.2016.02.007. Epub 2016 Feb 22. PubMed 26908089 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2011
First posted
Aug 22, 2011
Start
Sep 2011
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Results first posted
Oct 9, 2015
Last update
Jul 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01421134
Responsible party
Sponsor
First posted
Aug 22, 2011
Start date
Sep 2011
Primary completion
Oct 2014
Completion
Oct 2014
Results posted
Oct 9, 2015
Last update
Jul 15, 2016

Study contacts

Medical Director, MD
study director · Sumitomo Pharma America, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lurasidone

Start the discussion